APLS (Apellis Pharmaceuticals) Future 3-5Y Total Revenue Growth Rate : 17.76 (As of Apr. 13, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Apellis Pharmaceuticals Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Apellis Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate is 17.76.

Competitive Comparison of Apellis Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, Apellis Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apellis Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Apellis Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

Apellis Pharmaceuticals (NAS:APLS) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Apellis Pharmaceuticals Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Apellis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (NAS:APLS) » Definitions » Future 3-5Y Total Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

1JK:Germany

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Executives

James George Chopas	officer: See Remarks	950 WINTER STREET, WALTHAM MA 02451
David O. Watson	officer: General Counsel	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Mark Jeffrey Delong	officer: Senior Vice President	100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Adam J. Townsend	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Pascal Deschatelets	officer: Chief Operating Officer	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Karen Lewis	officer: Chief People Officer	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Jeffrey Eisele	officer: See Remarks	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Nur Nicholson	officer: Chief Technical Officer	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Timothy Eugene Sullivan	officer: Chief Financial Officer	800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199
Cedric Francois	director, 10 percent owner, officer: Chief Executive Officer	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Caroline Baumal	officer: Chief Medical Officer	C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
A. Sinclair Dunlop	director	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Lukas Scheibler	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Alec Machiels	director	505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022
Federico Grossi	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014